MEDIUMOutside partyCounterparty
Gilead
“10-K Item 1A: 'We expect our collaboration with Gilead to be a critical part of the development, manufacture and commercialization of our product candidates.'”
ASMB · Concentration risk · 10-K extracted
Assembly Biosciences (ASMB) concentration risks
Updated
The most significant concentration Assembly Biosciences discloses is Gilead, classified MEDIUM by disclosed size. Below: the full set from the latest 10-K — verbatim quotes, filing references, and a synthesis of what these exposures mean together.
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Source: Assembly Biosciences’s SEC Form 10-K filed — view the filing on SEC EDGAR ↗
At a glance
Disclosed-size breakdown · 1 disclosed concentration
HIGH0
MEDIUM1
LOW0
Disclosed concentrations
Each card carries a disclosed-size chip (HIGH / MEDIUM / LOW — how large the exposure is as a share of revenue, not how dangerous it is) and a nature tag: Built-in(the company’s own model, geography, or products) or Outside party (an external customer, supplier, or distributor it relies on).
TrendMatrix Research · concentration synthesis
What these concentrations mean together
updated 2026-07-06Assembly Biosciences' disclosed concentration risk is a single counterparty dependency: the company expects its collaboration with Gilead to be a critical part of the development, manufacture, and commercialization of its product candidates, a medium-share exposure by the filing's own disclosure. Because this is a dependency rather than a structural feature of the business, the risk is tied to the health and continuation of one partnership — if the Gilead collaboration were disrupted, renegotiated on worse terms, or discontinued, it would affect a meaningful part of how Assembly's pipeline gets developed, manufactured, and brought to market, given no other partner is named in the sources reviewed. This is a common structure for a clinical-stage biotech reliant on a larger partner's capital and infrastructure, but it does concentrate execution risk in one relationship rather than spreading it across multiple collaborators. No customer, supplier, geographic, or product-revenue concentration is disclosed alongside it in the sources reviewed here, so the entire concentration picture for Assembly rests on the durability of this single, medium-share partnership.
For the engine’s reasoning on ASMB’s current verdict — including which dimensions drove the score — see the per-dimension breakdown.
Industry peers · Biotechnology
Peer concentration profile
| Symbol | Name | HIGH | MEDIUM | LOW | Total |
|---|---|---|---|---|---|
| ACAD | ACADIA Pharmaceuticals Inc. | 2 | 0 | 0 | 2 |
| ABUS | Arbutus Biopharma Corporation | 1 | 1 | 0 | 2 |
| ABSI | Absci Corporation | 1 | 0 | 0 | 1 |
| ASMB● | Assembly Biosciences, Inc. | 0 | 1 | 0 | 1 |
| ABCL | AbCellera Biologics Inc. | 0 | 0 | 0 | 0 |
| ACHV | Achieve Life Sciences, Inc. | 0 | 0 | 0 | 0 |
Concentration counts reflect items disclosed in each peer’s most recent 10-K; disclosed-size classification uses TrendMatrix’s internal 10-K extraction taxonomy.